Taxotere® (docetaxel) receives 2 new European approvals for treatment of breast cancer
In addition to approving TAC for early breast cancer, the European Commission approved "Taxotere®, in combination with Herceptin® (trastuzumab), for the treatment of patients with metastatic breast cancer whose tumors over-express the Her2 gene. The Commission approval is based on the results of two separate large randomized international trials."
I must admit that I think my oncologist in the UK has been using this combination since the results of phase III became available, but it is very good news for patients whose doctors aren't as clued up.